Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 2018, Article ID 2057219, 10 pages
https://doi.org/10.1155/2018/2057219
Research Article

Cognitive-Enhancing Effect of a Hydroethanolic Extract of Crinum macowanii against Memory Impairment Induced by Aluminum Chloride in BALB/c Mice

1Drug and Toxicology Information Service (DaTIS), School of Pharmacy and Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, P.O. Box A 178, Avondale, Harare, Zimbabwe
2School of Pharmacy, University of Zimbabwe, P.O. Box MP167, Mount Pleasant, Harare, Zimbabwe

Correspondence should be addressed to Mohammed S. Jilani; moc.liamg@jbiqaas

Received 23 January 2018; Revised 16 August 2018; Accepted 27 August 2018; Published 4 October 2018

Academic Editor: Antonio Orlacchio

Copyright © 2018 Mohammed S. Jilani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Burns and S. Iliffe, “Alzheimer’s disease,” BMJ, vol. 338, p. b158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Sevigny, P. Chiao, T. Bussière et al., “The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease,” Nature, vol. 537, no. 7618, pp. 50–56, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Hardy and D. Allsop, “Amyloid deposition as the central event in the aetiology of Alzheimer’s disease,” Trends in Pharmacological Sciences, vol. 12, no. 10, pp. 383–388, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Mudher and S. Lovestone, “Alzheimer’s disease-do tauists and baptists finally shake hands?” Trends in Neurosciences, vol. 25, no. 1, pp. 22–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Bertram and R. E. Tanzi, “Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses,” Nature Reviews Neuroscience, vol. 9, no. 10, pp. 768–778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Folch, D. Petrov, M. Ettcheto et al., “Current research therapeutic strategies for Alzheimer’s disease treatment,” Neural Plasticity, vol. 2016, Article ID 8501693, 15 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Bartus, R. Dean, B. Beer, and A. Lippa, “The cholinergic hypothesis of geriatric memory dysfunction,” Science, vol. 217, no. 4558, pp. 408–414, 1982. View at Publisher · View at Google Scholar
  8. J. L. Cummings and C. Back, “The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease,” The American Journal of Geriatric Psychiatry, vol. 6, Supplement 1, no. 2, pp. S64–S78, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Farlow, “A clinical overview of cholinesterase inhibitors in Alzheimer’s disease,” International Psychogeriatrics, vol. 14, Supplement 1, pp. 93–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Herrmann, S. A. Chau, I. Kircanski, and K. L. Lanctôt, “Current and emerging drug treatment options for Alzheimer’s disease,” Drugs, vol. 71, no. 15, pp. 2031–2065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. P. Murray, M. B. Faraoni, M. J. Castro, N. P. Alza, and V. Cavallaro, “Natural AChE inhibitors from plants and their contribution to Alzheimer’s disease therapy,” Current Neuropharmacology, vol. 11, no. 4, pp. 388–413, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Refaat, M. S. Kamel, M. A. Ramadan, and A. A. Ali, “Crinum and an endless source of bioactive principles: a review. Part 1-Crinum alkaloids: lycorine-type alkaloids,” International Journal of Pharmaceutical Sciences and Research, vol. 3, no. 7, pp. 1883–1890, 2012. View at Google Scholar
  13. J. Refaat, M. S. Kamel, M. A. Ramadan, and A. A. Ali, “Crinum and an endless source of bioactive principles: a review, part II. Crinum alkaloids: crinine-type alkaloids,” International Journal of Pharmaceutical Sciences and Research, vol. 3, no. 9, p. 3091, 2012. View at Google Scholar
  14. J. Refaat, M. S. Kamel, M. A. Ramadan, and A. A. Ali, “Crinum, III, an endless source of bioactive principles: a review. Part 1crinum alkaloids: belladine-, galanthamine-, lycorenine-, tazettine-type alkaloids and other minor types,” International Journal of Pharmaceutical Sciences and Research, vol. 3, no. 10, p. 3630, 2012. View at Google Scholar
  15. A. Maroyi, “A review of ethnoboatany, therapeutic value, phytochemistry and pharmacology of Crinum macowanii Baker: a highly traded bulbous plant in Southern Africa,” Journal of Ethnopharmacology, vol. 194, pp. 595–608, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. E. E. Elgorashi, S. E. Drewes, and J. Van Staden, “Organ-to-organ and seasonal variation in alkaloids from Crinum macowanii,” Fitoterapia, vol. 73, no. 6, pp. 490–495, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. E. E. Elgorashi, G. I. Stafford, and J. van Staden, “Acetylcholinesterase enzyme inhibitory effects of Amaryllidaceae alkaloids,” Planta Medica, vol. 70, no. 3, pp. 260–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. A. T. Mugwagwa, L. L. Gadaga, W. Pote, and D. Tagwireyi, “Antiamnesic effects of a hydroethanolic extract of Crinum macowanii on scopolamine-induced memory impairment in mice,” Journal of Neurodegenerative Diseases, vol. 2015, Article ID 242505, 9 pages, 2015. View at Publisher · View at Google Scholar
  19. G. M. Berlyne, J. Ben Ari, E. Knopf, R. Yagil, G. Weinberger, and G. M. Danovitch, “Aluminium toxicity in rats,” Lancet, vol. 299, no. 7750, pp. 564–568, 1972. View at Publisher · View at Google Scholar · View at Scopus
  20. J. R. McDermott, A. I. Smith, K. Iqbal, and H. M. Wisniewski, “Brain aluminum in aging and Alzheimer disease,” Neurology, vol. 29, no. 6, pp. 809–814, 1979. View at Publisher · View at Google Scholar
  21. F. Ashall and A. M. Goate, “Role of the β-amyloid precursor protein in Alzheimer’s disease,” Trends in Biochemical Sciences, vol. 19, no. 1, pp. 42–46, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. I. Linardaki, M. G. Orkoula, A. G. Kokkosis, F. N. Lamari, and M. Margarity, “Investigation of the neuroprotective action of saffron (Crocus sativus L.) in aluminum-exposed adult mice through behavioral and neurobiochemical assessment,” Food and Chemical Toxicology, vol. 52, pp. 163–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Bromley-Brits, Y. Deng, and W. Song, “Morris water maze test for learning and memory deficits in Alzheimer’s disease model mice,” Journal of Visualized Experiments, no. 53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Doreddula, S. R. Bonam, D. P. Gaddam, B. S. R. Desu, N. Ramarao, and V. Pandy, “Phytochemical analysis, antioxidant, antistress, and nootropic activities of aqueous and methanolic seed extracts of ladies finger (Abelmoschus esculentus L.) in mice,” The Scientific World Journal, vol. 2014, Article ID 519848, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Yadav, S. Chatterji, S. K. Gupta, and G. Watal, “Preliminary phytochemical screening of six medicinal plants used in traditional medicine,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 5, pp. 539–542, 2014. View at Google Scholar
  26. R. D’Hooge and P. P. De Deyn, “Applications of the Morris water maze in the study of learning and memory,” Brain Research Reviews, vol. 36, no. 1, pp. 60–90, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. V. Terry Jr and J. J. Buccafusco, “Spatial navigation (water maze) tasks,” in Methods of Behavior Analysis in Neuroscience, pp. 169–182, CRC Press, 2009. View at Publisher · View at Google Scholar
  28. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Wirths, G. Multhaup, and T. A. Bayer, “A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide - the first step of a fatal cascade,” Journal of Neurochemistry, vol. 91, no. 3, pp. 513–520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Kawahara and M. Kato-Negishi, “Link between aluminum and the pathogenesis of Alzheimer’s disease: the integration of the aluminum and amyloid cascade hypotheses,” International Journal of Alzheimer’s Disease, vol. 2011, Article ID 276393, 17 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Praticò, K. uryu, S. Sung, S. Tang, J. Q. Trojanowski, and V. M. Y. Lee, “Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice,” The FASEB Journal, vol. 16, no. 9, pp. 1138–1140, 2002. View at Publisher · View at Google Scholar
  32. D. Schuster, M. Spetea, M. Music et al., “Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors,” Bioorganic & Medicinal Chemistry, vol. 18, no. 14, pp. 5071–5080, 2010. View at Publisher · View at Google Scholar · View at Scopus